Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Vir Biotechnology (VIR)

Vir Biotechnology CEO Marianne De Backer Also Named President

Neutral Impact 3 of 5 leadership Written later

On March 4, 2026, Vir Biotechnology's board appointed Chief Executive Officer Marianne De Backer to the additional position of President. The filing describes no change to her compensation and no financial results, so the change is administrative in nature and reflects a broader role for the chief executive.

Key points

  • Marianne De Backer, Ph.D., remains Chief Executive Officer and principal executive officer and adds the title of President.
  • Board of Directors made the appointment on March 4, 2026.
  • Filing states no family relationship and no related-party transactions requiring disclosure for Dr. De Backer.
  • Biographical details are incorporated by reference from the proxy statement filed April 17, 2025.

The filing

CompanyVir Biotechnology (VIR)
Form8-K, current report
Filed with the SECMar 4, 2026, 4:01 PM ET
Accession number0001193125-26-091447

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.